Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN — Stella

Recruiting

Back to Lupus Nephritis (LN) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Institute of Nephrology, Zhong Da Hospital, Southeast University School of Medicine, Nanjing, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Enrollment target

~105 participants

Started

November 2025

Primary completion

November 2027

Age range

18 Years – 75 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov